Table 5. Extended fatality risk during ~ 60 days following the onset of acute diarrhea among cases and controls aged 0–23 months*.
| African sites | Asian sites | |||||
|---|---|---|---|---|---|---|
| Group | Total subjects | No. of deaths during ~60 days of follow-up | Percent (95% CI) | Total subjects | No. of deaths during ~60 days of follow-up | Percent (95% CI) |
| Total MSD cases | 4552 | 169 | 3.7% (3.2%-4.3%) | 3828 | 26 | 0.7% (0.4%-1.0%) |
| Cryptosporidium-positive MSD cases | 643 | 41 | 6.4% (4.6%-8.6%) | 451 | 4 | 0.9% (0.2%-2.3%) |
| Cryptosporidium-negative MSD cases | 3909 | 128 | 3.3% (2.7%-3.9%) | 3377 | 22 | 0.7% (0.4%-1.0%) |
| All controls of MSD cases | 6258 | 37 | 0.6% (0.4%-0.8%) | 5204 | 3 | 0.06% (0.01%-0.2%) |
| Controls of Cryptosporidium-positive MSD cases | 928 | 4 | 0.4% (0.1%-1.1%) | 573 | 0 | 0.0% (0.0%-0.6%) |
| Total LSD cases | 1139 | 6 | 0.5% (0.2%-1.1%) | 1035 | 5 | 0.5% (0.2%-1.1%) |
| Cryptosporidium-positive LSD cases | 139 | 1 | 0.7% (0.1%-3.9%) | 72 | 1 | 1.4% (0.3%-7.5%) |
| Cryptosporidium-negative LSD cases | 1000 | 5 | 0.5% (0.2%-1.1%) | 963 | 4 | 0.4% (0.2%-1.1%) |
| All controls of LSD cases | 1261 | 4 | 0.3% (0.1%-0.8%) | 1554 | 3 | 0.2% (0.07%-0.5%) |
| Controls of Cryptosporidium-positive LSD cases | 156 | 1 | 0.6% (0.02%-3.5%) | 102 | 0 | 0.0% (0.0%-3.6%) |
* MSD: moderate-to-severe diarrhea (GEMS-1 and GEMS-1A data), LSD: less severe diarrhea (GEMS-1A data). This table includes data only for cases with Cryptosporidium results and non-missing data on vital status at follow-up, and their matched controls.